Personal Genome Diagnostics, Blueprint Medicines to ID Novel Drug Targets in Cancer | GenomeWeb

NEW YORK (GenomeWeb News) – Cancer genome analysis firm Personal Genome Diagnostics said today that it will collaborate with Blueprint Medicines to search for novel kinase targets for cancer drugs.

Personal Genome Diagnostics will use exome sequencing as well as its own proprietary digital karyotyping technology, which it licensed from Johns Hopkins, to analyze copy number changes in cancer genomes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.

In Science this week: new chromatin imaging approach, and more.